Characterized by loss of expression of the estrogen receptor (ER), progesterone receptor (PR), and a lack of over-expression of the human epidermal growth factor receptor 2 (HER2), TNBC is a highly aggressive and metastatic disease with a very overall poor prognosis with a current five-year survival rate of less than 30%. Here, PGR is linked to metastatic neoplasm.